Celsion Presents Heat Activated Liposomes At CaP Cure Annual Retreat.

Business Editors/Health & Medical Writers

COLUMBIA, Md.--(BUSINESS WIRE)--Sept. 20, 2002

CELSION CORPORATION (AMEX:CLN) announced today that Dr. Donald "Skip" Trump, the principal investigator for Celsion's upcoming Phase I prostate cancer trial, will present a poster detailing Celsion's "New drug delivery approach for the treatment of prostate cancer" at the 2002 Annual Scientific Retreat of CaP CURE, the Association for the Cure of Cancer in the Prostate, in Washington D.C., on September 20-22, 2002.

Since its inception in 1993, CaP CURE has been a leader in raising awareness regarding prostate cancer and has led the efforts to search for a cure. Largely though CaP CURE's efforts U.S. government support for prostate cancer research has increased from $60 million to $430 million annually. In addition, CaP CURE has awarded more than $104 million to fund 1,000 medical research projects worldwide.

Dr. Trump, a national cancer leader in innovative clinical trials in prostate cancer and Senior Vice President for Clinical Research at Roswell Park Cancer Institute in Buffalo, New York, will report on the anticipated start of human clinical trials of Celsion's investigational therapy for the treatment of prostate cancer.

Celsion's therapeutic approach combines its proprietary focused-heat thermotherapy delivery system, the Microfocus BPH 800 Microwave Urethroplasty(TM) system, with a heat-sensitive liposome that is designed, when activated, to deliver a chemotherapeutic agent to the targeted tumor site.

The Company will undertake Phase I clinical trials at Roswell Park, one of the leading cancer centers in the United States.

Celsion's investigational drug delivery technology is based upon the work of David Needham, Ph.D. and Mark Dewhirst, DVM, Ph.D.

According to Dr. Needham, Professor of Material Sciences, Department of Mechanical Engineering and Material Science at Duke University and the inventor of the temperature-sensitive liposome utilized by the Celsion system, the technology employs specially designed liposomes, which open when heated.

When the anticancer drug encapsulated in these liposomes is injected into the bloodstream of a cancer patient and the cancer treatment site is subjected to mild heat, the liposomes open and rapidly release their "load" of chemotherapeutic drugs directly at the treatment site.

This release is significantly more rapid than in conventional liposomal therapy. As reported in Cancer Research - Advances in Brief (March 1, 2000), this increased concentration of drug in the treatment area caused long-term complete regression of tumors in all of the mice treated in the initial small animal studies of the Celsion treatment system.

Celsion holds an exclusive license from Duke University for the use of Duke's patented temperature-sensitive liposome technology.

Dr. Augustine Cheung, Celsion's founder and Chief Executive Officer commented, "We are very excited to move forward into this new field of cancer treatment. Demonstrating that the combination of our focused-heat therapy and temperature-sensitive liposomes can be effective in the treatment of prostate cancer will be a first step. If we are successful, this combination could serve as a platform for other types of cancer treatments, including the use of our temperature-sensitive liposome technology to encapsulate a range of cancer-fighting drugs. Our thermo-liposome development efforts, in conjunction with our ongoing pivotal breast cancer trials, in which we are attempting to demonstrate that heat alone can ablate small breast cancer tumors and, in combination with chemotherapy, shrink large breast cancer tumors, should provide a strong foundation for Celsion in the cancer therapeutic market."

About Celsion: Celsion Corporation, based in Columbia, Maryland, is a research and development company dedicated to commercializing medical treatment systems for cancer and other diseases using focused-heat technology delivered by patented microwave technology.

Celsion has research, license or commercialization agreements with leading institutions such as Duke University Medical Center, Massachusetts Institute of Technology, Harbor UCLA Medical Center, the Center for Breast Surgery at Columbia Hospital in Florida, Montefiore Medical Center, Memorial Sloan Kettering Cancer Center in New York, Roswell Park Cancer Institute in Buffalo, New York, and Duke University.

For more information on Celsion, visit our website: http//www.celsion.com.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; possible changes in cost and timing of development and testing, capital structure, and other financial items; changes in approaches to medical treatment; introduction of new products by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.